Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
Jazz Pharmaceuticals (Nasdaq: JAZZ) has entered into a global licensing agreement with Saniona (Nasdaq OMX: SANION) for exclusive worldwide rights to develop and commercialize SAN2355, a preclinical asset for epilepsy treatment. Jazz will pay $42.5 million upfront to Saniona.
The agreement includes potential payments of up to $192.5 million in development and regulatory milestones, including $7.5 million for Phase 1 initiation, up to $800 million in commercial milestones, and tiered royalties from mid-single digits to low-double digits on net sales.
SAN2355 is a subtype-selective Kv7.2/Kv7.3 activator designed to overcome limitations of non-selective Kv7-targeting compounds. Jazz will lead and fund development, regulatory submissions, and global commercialization efforts.
Jazz Pharmaceuticals (Nasdaq: JAZZ) ha stipulato un accordo di licenza globale con Saniona (Nasdaq OMX: SANION) per i diritti esclusivi mondiali di sviluppo e commercializzazione di SAN2355, un candidato preclinico per il trattamento dell'epilessia. Jazz verser脿 a Saniona un pagamento iniziale di 42,5 milioni di dollari.
L'accordo prevede pagamenti aggiuntivi legati a risultati di sviluppo e regolatori fino a 192,5 milioni di dollari, inclusi 7,5 milioni di dollari per l'avvio della Fase 1, e fino a 800 milioni di dollari in milestone commerciali, oltre a royalty a scaglioni che vanno da una percentuale media bassa fino a una percentuale bassa a due cifre sul fatturato netto.
SAN2355 猫 un attivatore selettivo per i sottotipi Kv7.2/Kv7.3 progettato per superare i limiti dei composti non selettivi che mirano a Kv7. Jazz guider脿 e finanzier脿 lo sviluppo, le sottomissioni regolatorie e la commercializzazione globale.
Jazz Pharmaceuticals (Nasdaq: JAZZ) ha suscrito un acuerdo de licencia global con Saniona (Nasdaq OMX: SANION) para obtener los derechos exclusivos mundiales de desarrollar y comercializar SAN2355, un activo precl铆nico para el tratamiento de la epilepsia. Jazz pagar谩 a Saniona un anticipo de 42,5 millones de d贸lares.
El acuerdo contempla pagos adicionales por hitos de desarrollo y regulatorios por hasta 192,5 millones de d贸lares, incluido un pago de 7,5 millones por el inicio de la Fase 1, hasta 800 millones de d贸lares en hitos comerciales, y regal铆as escalonadas que van desde cifras medias bajas hasta cifras bajas de dos d铆gitos sobre las ventas netas.
SAN2355 es un activador selectivo de los subtipos Kv7.2/Kv7.3 dise帽ado para superar las limitaciones de los compuestos no selectivos que act煤an sobre Kv7. Jazz liderar谩 y financiar谩 el desarrollo, las presentaciones regulatorias y la comercializaci贸n global.
Jazz Pharmaceuticals (Nasdaq: JAZZ)电� Saniona (Nasdaq OMX: SANION)瓿� 鞝� 靹戈硠 霃呾爯鞝� 甓岆Μ毳� 攵�鞐晿电� 旮�搿滊矊 霛检澊靹犾姢 瓿勳暯鞚� 觳搓舶頃橃棳 臧勳 旃橂鞖� 鞝勳瀯靸� 頉勲炒氍检 SAN2355鞚� 臧滊皽 氚� 靸侅梾頇� 甓岉暅鞚� 頇曤炒頄堨姷雼堧嫟. Jazz电� Saniona鞐� 齑堦赴旮� 4,250毵� 雼煬毳� 歆�旮夗暕雼堧嫟.
氤� 瓿勳暯鞐惖鐢 鞛勳儊 氚� 攴滌牅 毵堨澕鞀ろ啢鞙茧 斓滊寑 1鞏� 9,250毵� 雼煬鞚� 於旉皜 歆�旮� 臧�電レ劚鞚� 韽暔霅橂┌, 鞐赴鞐惖鐢 1靸� 臧滌嫓毳� 鞙勴暅 750毵� 雼煬臧� 韽暔霅╇媹雼�. 霕愴暅 靸侅梾鞝� 毵堨澕鞀ろ啢鞙茧 斓滊寑 8鞏� 雼煬鞕� 靾滊Г於滌棎 雽�頃� 欷戩爛(欷戧皠 雼澕鞛愲Μ)鞐愳劀 雮潃 霊� 鞛愲靾橁箤歆�鞚� 瓿勲嫧鞁� 搿滌棿韹�臧� 鞝侅毄霅╇媹雼�.
SAN2355电� 牍勳劆韮濎爜 Kv7 響滌爜 頇旐暕氍检潣 頃滉硠毳� 攴闺车頃橂弰搿� 靹り硠霅� Kv7.2/Kv7.3 靻岇晞順� 靹犿儩鞝� 頇滌劚鞝滌瀰雼堧嫟. Jazz臧� 臧滊皽, 攴滌牅 鞝滌稖 氚� 鞝� 靹戈硠 靸侅梾頇� 鞛戩梾鞚� 欤茧弰頃橁碃 鞛愱笀鞚� 歆�鞗愴暕雼堧嫟.
Jazz Pharmaceuticals (Nasdaq: JAZZ) a conclu un accord de licence mondial avec Saniona (Nasdaq OMX: SANION) pour obtenir les droits exclusifs mondiaux de d茅velopper et commercialiser SAN2355, un candidat pr茅clinique pour le traitement de l'茅pilepsie. Jazz versera 脿 Saniona un paiement initial de 42,5 millions de dollars.
L'accord pr茅voit des paiements 茅ventuels li茅s 脿 des jalons de d茅veloppement et r茅glementaires pouvant atteindre 192,5 millions de dollars, y compris 7,5 millions de dollars au d茅marrage de la phase 1, jusqu'脿 800 millions de dollars en jalons commerciaux, ainsi que des redevances 茅chelonn茅es allant d'un faible chiffre m茅dian 脿 un bas chiffre 脿 deux chiffres sur les ventes nettes.
SAN2355 est un activateur s茅lectif des sous-types Kv7.2/Kv7.3 con莽u pour pallier les limites des compos茅s non s茅lectifs ciblant Kv7. Jazz prendra en charge et financera le d茅veloppement, les soumissions r茅glementaires et la commercialisation mondiale.
Jazz Pharmaceuticals (Nasdaq: JAZZ) hat eine globale Lizenzvereinbarung mit Saniona (Nasdaq OMX: SANION) geschlossen, die Jazz exklusive weltweite Rechte zur Entwicklung und Vermarktung von SAN2355, einem pr盲klinischen Wirkstoffkandidaten zur Behandlung von Epilepsie, einr盲umt. Jazz zahlt an Saniona eine Vorauszahlung in H枚he von 42,5 Millionen US-Dollar.
Die Vereinbarung sieht weitere leistungsabh盲ngige Zahlungen bis zu 192,5 Millionen US-Dollar f眉r Entwicklungs- und Zulassungserfolge vor, darunter 7,5 Millionen US-Dollar bei Beginn von Phase 1, bis zu 800 Millionen US-Dollar an kommerziellen Meilensteinen sowie gestaffelte Lizenzgeb眉hren von mittleren einstelligen bis zu niedrigen zweistelligen Prozents盲tzen auf den Nettoumsatz.
SAN2355 ist ein subtypselektiver Kv7.2/Kv7.3-Aktivator, der entwickelt wurde, um die Einschr盲nkungen nichtselektiver Kv7-wirkender Verbindungen zu 眉berwinden. Jazz wird die Entwicklung, regulatorische Einreichungen und die weltweite Kommerzialisierung f眉hren und finanzieren.
- Upfront payment of $42.5 million strengthens Saniona's financial position
- Potential for substantial milestone payments totaling up to $992.5 million
- Partnership with Jazz leverages their expertise in epilepsy drug development and commercialization
- SAN2355's selective mechanism potentially offers best-in-class treatment approach
- SAN2355 is still in preclinical stage, indicating long development timeline ahead
- Significant clinical development and regulatory risks remain as an early-stage asset
Insights
Jazz's $42.5M upfront deal for Saniona's epilepsy drug SAN2355 could deliver significant long-term value with minimal near-term revenue impact.
Jazz Pharmaceuticals has secured exclusive global rights to Saniona's preclinical epilepsy asset SAN2355 through a substantial licensing deal worth
The transaction's structure is particularly noteworthy. The
SAN2355's mechanism as a selective Kv7.2/Kv7.3 activator represents an important scientific approach. Unlike existing non-selective Kv7 activators which can cause significant side effects, SAN2355's subtype selectivity could potentially deliver improved efficacy with fewer adverse events - a critical differentiator in the competitive epilepsy market. While still in preclinical development, the compound's potential as a "best-in-class" therapy suggests Jazz sees compelling early data supporting its investment.
For Saniona, this deal provides crucial non-dilutive capital to advance other pipeline programs while leveraging Jazz's established development and commercialization capabilities. The
SAN2355's mechanism as a subtype-selective Kv7.2/Kv7.3 activator represents a potentially significant advancement in epilepsy treatment. Potassium voltage-gated (Kv7) channels play a crucial role in regulating neuronal excitability, making them important targets for anti-seizure medications. However, first-generation Kv7 modulators like ezogabine (retigabine) were hampered by off-target effects due to their non-selective activation across multiple Kv7 subtypes, leading to side effects including urinary retention and blue skin discoloration that ultimately limited clinical utility.
SAN2355's selective targeting of Kv7.2/Kv7.3 heteromeric channels - the specific subtypes most relevant to epilepsy - potentially addresses these limitations. These particular channel subtypes generate the neuronal M-current, which stabilizes resting membrane potential and regulates neuronal firing. By specifically enhancing this current in neurons without affecting other Kv7 subtypes found in cardiac tissue (Kv7.1) or other organ systems, SAN2355 could theoretically deliver anti-seizure efficacy with an improved safety profile.
While still in preclinical development, Jazz's substantial financial commitment suggests the compound has shown promising early results in relevant animal models. The company's experience with oxybate products for neurological conditions positions them well to navigate the complex development pathway for CNS drugs. The immediate research focus will likely involve completing IND-enabling studies including pharmacokinetics, toxicology assessments, and manufacturing scale-up, with first-in-human studies potentially beginning within 12-18 months based on the milestone structure.
Though not discussed in the release, SAN2355's potential may extend beyond epilepsy to other neurological conditions characterized by neuronal hyperexcitability, including neuropathic pain, certain psychiatric disorders, and potentially neurodegenerative diseases - providing multiple paths to maximize the asset's value.
Saniona to receive US
Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications
For
"Our collaboration with Jazz leverages their leading position in epilepsy and their strong track record of rapidly advancing clinical development programs and effectively commercializing novel therapies in neuroscience, positioning SAN2355 as a promising option for epilepsy and neurological conditions, while enabling us to advance several of our other valuable pipeline programs to key inflection points," said Thomas Feldthus, CEO of Saniona. "Jazz's commitment to develop life-changing medicines for people with serious diseases aligns with our mission to improve outcomes for those affected by neurological and psychiatric disorders, and both companies aim to expand treatment possibilities for patients in need."
"SAN2355 is a unique and highly promising preclinical asset that has the potential to become a best-in-class Kv7 activator for the treatment of epilepsy. We are pleased to enter this exclusive agreement with Saniona to lead the SAN2355 clinical development program," said听Robert Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. "This transaction further expands our early-stage neuroscience pipeline building on our existing expertise in the treatment of epilepsy and our R&D team remains committed to developing novel approaches to improving treatment options for people living with epilepsy and other neurologic conditions."
Transaction Terms
Under the terms of the exclusive licensing agreement, Saniona will receive an upfront payment of US
About SAN2355
SAN2355 is a preclinical, selective small molecule activator of Kv7.2/Kv7.3 potassium channels, a mechanism validated for seizure suppression. Prior Kv7-targeting agents have demonstrated clinical efficacy, but dosing appears to be limited by adverse events associated with off-target activation. SAN2355 is uniquely selective for Kv7.2/Kv7.3, the Kv7-subtypes responsible for seizure suppression, and avoids activation of other Kv7-subtypes. This selectivity enables SAN2355 to deliver dosing to optimal efficacy and supports its potential as a best-in-class treatment for epilepsy.
About鈥疛azz Pharmaceuticals听
Jazz Pharmaceuticals plc鈥�(Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases 鈥� often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in鈥疍ublin, Ireland鈥痺ith research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit鈥�www.jazzpharmaceuticals.com鈥痜or more information.听
About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company's internal pipeline includes SAN2219 for epilepsy and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in
Jazz Pharmaceuticals听plc Caution Concerning Forward-Looking Statements听
This press release contains forward-looking statements, including, but not limited to, statements related to SAN2355's potential to be a best-in-class Kv7 activator for the treatment of epilepsy; the potential future development, manufacturing, regulatory and commercialization activities; potential future payments by Jazz Pharmaceuticals to Saniona for development, regulatory and commercial milestones as well as tiered royalties based on future net sales; and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: Jazz Pharmaceuticals' ability to achieve the expected benefits (commercial or otherwise) from the license agreement; pharmaceutical product development and clinical success thereof; the regulatory approval process; effectively commercializing any product candidates; and other risks and uncertainties affecting Jazz Pharmaceuticals, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and future filings and reports by the Company. Other risks and uncertainties of which Jazz Pharmaceuticals is not currently aware may also affect Jazz Pharmaceuticals' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by Jazz Pharmaceuticals on its website or otherwise. Jazz Pharmaceuticals undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Jazz Pharmaceuticals Contacts:听
Investors:听 听
Jack Spinks听
Executive Director, Investor Relations
Pharmaceuticals plc
[email protected] 听
Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Saniona Contact:
Johnny Stilou
CFO
Saniona AB听
[email protected]听
+45 21 227 227
听
View original content to download multimedia:
SOURCE Jazz Pharmaceuticals plc
FAQ
What is the value of Jazz Pharmaceuticals' licensing agreement with Saniona for SAN2355?
What is SAN2355 and how does it work?
What development stage is JAZZ's new epilepsy drug SAN2355 in?
Who will be responsible for developing and commercializing SAN2355?
What are the milestone payments in the Jazz-Saniona agreement?
